Depending on the type of alternative payment models, it could be more difficult or easier for practices to find overlaps and participate in multiple models, said Mike Fazio, senior vice president of client services, Archway Health.
Depending on the type of alternative payment models, it could be more difficult or easier for practices to find overlaps and participate in multiple models, said Mike Fazio, senior vice president of client services, Archway Health.
Transcript
As the country moves to value-based care, the number of alternative payment models is growing, and many practices are participating in more than one. Are they having trouble balancing multiple models?
It depends on the model. So, OCM [Oncology Care Model] involves so much of the patient mix of OCM practices and because of the care transformation components of the program from the get-go it’s been an area of focus for anyone that’s in OCM.
In some of the other programs, like BPCI [Bundled Payments for Care Improvement] Advanced, there is intersection and overlap with other programs, like the ACO [accountable care organization] program, for example. And those models, thought, BPCI is a great avenue to incent specialists within a primary care model, like an ACO. So, it does differ.
But from an OCM perspective we see that participants are very focused and with the movement toward downside risk in OCM, for those practices that make that choice this fall, definitely more focus on OCM because of that. Whereas a one-sided model, it’s a different beginning than being in a risk-based model.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More